
Feb 24 (Reuters) - Bristol-Myers Squibb Co BMY.N:
U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL MYERS SQUIBB’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO® PLUS YERVOY® FOR PATIENTS WITH UNRESECTABLE OR METASTATIC MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT...
BRISTOL-MYERS SQUIBB CO - FDA ASSIGNS TARGET ACTION DATE OF JUNE 23, 2025
Source text: ID:nBw2tnHFDa
Further company coverage: BMY.N